Integrating $\text{BRAF}^{\text{V600E}}$ mutation, ultrasonic and clinicopathologic characteristics for predicting the risk of cervical central lymph node metastasis in papillary thyroid carcinoma

Zheng Zhang1, Xin Zhang1, Yifei Yin2, Shuangshuang Zhao1, Keke Wang1, Mengyuan Shang1, Baoding Chen1* and Xincai Wu1*

Abstract

Background: The advantages of prophylactic central lymph node dissection (CLND) for clinically node-negative patients remained a great deal of controversies. Our research was aimed to analyze the relationship between cervical central lymph node metastasis (CLNM) and $\text{BRAF}^{\text{V600E}}$ mutation, ultrasonic and clinicopathologic characteristics in papillary thyroid carcinoma (PTC).

Methods and materials: In current study, a total of 112 consecutive PTC patients who experienced thyroidectomy plus cervical central neck dissection were included in our research. All PTC were pre-operatively analyzed by ultrasonic features, including tumor size, multifocality or not, tumor location, internal components, echogenicity, microcalcification, margins, orientation, taller than wide shape, and internal vascularity. The presence of clinicopathologic factors, including age, sex, T stage, Hashimoto's thyroiditis, and $\text{BRAF}^{\text{V600E}}$ mutation was then investigated. Univariate and multivariate analysis were conducted to check into the relationship between predictive factors and cervical CLNM in PTC patients, and then a predictive model was also established.

Results: Pathologically, 58.0% (65/112) of the PTC patients harbored cervical CLNM. Univariate and multivariate analysis were conducted to identify age < 55 years, tumor size > 10 mm, microcalcification, non-concomitant Hashimoto's thyroiditis and $\text{BRAF}^{\text{V600E}}$ mutation were predictive factors for cervical CLNM in PTC. The risk score for cervical CLNM in PTC patients was calculated: risk score = 1.284 × (if age < 55 years) + 1.241 × (if tumor size > 10 mm) + 1.143 × (if microcalcification) – 2.097 × (if concomitant Hashimoto's thyroiditis) + 1.628 × (if $\text{BRAF}^{\text{V600E}}$ mutation).

Conclusion: Age < 55 years old, PTC > 10 mm, microcalcification, non-concomitant Hashimoto's thyroiditis and $\text{BRAF}^{\text{V600E}}$ mutation are predictive factors for cervical CLNM. $\text{BRAF}^{\text{V600E}}$ mutation by pre-operative US-FNA technology synergized with clinicopathologic and ultrasonic features is expected to guide the appropriate surgical management for PTC patients.

Keywords: Papillary thyroid carcinoma, Cervical central lymph node metastases, Ultrasonic features, Clinicopathologic factors, $\text{BRAF}^{\text{V600E}}$ mutation

Introduction

Papillary thyroid carcinoma (PTC) is the most prevalent histological type of thyroid carcinoma [1], which is largely owing to the extensive utilization of
high-resolution ultrasound (US) and fine-needle aspiration (FNA) technology [2–4]. Most of PTC patients require an satisfactory clinical prognosis, after the suitable surgical resection and medical treatment [5]. However, accumulating evidence has documented that 40–60% of PTC cases harbor cervical central lymph node metastasis (CLNM), which could increase the possibility of recurrence, distant metastasis and even contribute to PTC-related deaths [6]. Although development in advance of evidence-based guidelines for PTC management, the advantages of prophylactic central lymph node dissection (CLND) in PTC patients without clinical evidence of cervical CLNM remains a great deal of controversies [7, 8]. Some claim that prophylactic CLND could reduce the recurrence rate of PTC to avoid second dissection, while others argue that patients may not gain any benefit, yet suffer from severe complications, including recurrent laryngeal nerve injury and low parathyroid function [9, 10].

High-frequency US are commonly performed for decision-making in the surgical management of malignant PTC. Solid component, hyper-echogenicity, microcalcification, irregular shapes, poorly defined margins and taller-than-wide shapes are malignant US characteristics that are helpful to judge the malignancy of PTC [11, 12]. Unfortunately, it is challenging to search cervical CLNM attributed to the gas interference in the trachea and esophagus, causing a diagnostic accuracy of merely 30% [13, 14]. US-guided fine-needle aspiration biopsy (FNAB) is widely used to increase the diagnostic accuracy by cytologic and genomic detection. B-type Raf (BRAF) kinase mutations on exon 15 is related to the protein kinase pathway and leads to proliferation and metastasis of PTC [15, 16]. There are still greatly controversies regarding the value of BRAF gene in predicting cervical CLNM [17, 18]. Virk and colleagues have reported PTC patients bearing BRAF mutation were more likely to have cervical CLNM features [19], but one opposite research documented that BRAF mutation was not a risk factor for CLNM in PTC patients [20].

In our study, we also retrospectively reviewed 112 consecutive PTC patients who experienced thyroidectomy plus prophylactic cervical CLND. Univariate and multivariate analysis were also conducted to estimate the relationship between cervical CLNM and BRAF mutation, ultrasonic and clinicopathologic features in patients harboring PTC. Our research is aimed to collaborate BRAF V600E mutation through preoperative US-FNA technology with clinicopathologic and US characteristics for guiding the suitable therapeutic management of PTC.

Methods and materials
This study design followed the international regulations according to the Declaration of Helsinki. Our research was approved by the Ethical Committee of the Affiliated Hospital of Jiangsu University (SWYXLL20190225-2) and written informed consent was obtained from participants.

US and clinicopathologic analysis
Between January 2020 and December 2020, a total of 112 consecutive PTC patients who experienced thyroidectomy plus with routinely prophylactic CLND were included in our investigation. All participants had experienced pre-operative US scanning and postoperative pathology to diagnose PTC. The inclusion criteria were retained: (a) patients more than 18 years of age; (b) the US images should be retrievable; (c) the US inspections should be conducted within one month before thyroidectomy; (d) PTC with or without cervical LNM should be confirmed by pathological specimens. The exclusion criteria were retained: (a) PTC contained coarse calcifications; (b) US information was insufficient; (c) thyroid nodules were pathologically confirmed as other kinds of thyroid carcinomas. Of note, the largest nodule was picked out into our research when participants with multiple malignant PTCs.

US evaluation
Participants were required to lie supine with their head slightly bent back. PTC was present in the center of the US screen, and sufficient neighbor thyroid tissue was displayed in the one graph. The targeted PTC was scanned from left to right and from top to bottom. The graphs of the targeted PTC were recorded transversely and longitudinally on gray-scale modality. The US images were interpreted by two experienced radiologists who were unaware of any information about participants’ identity and pathological results. The disagreement PTC was re-evaluated and decided by another experienced radiologist. The following US characteristics of targeted PTC were analyzed: diameter on gray-scale US (>10 mm/≤10 mm in size), tumor location (left, right and isthmus), multiple PTCs (present/absent), solid (present/absent), marked hypo-echogenicity/hypo-echogenicity (present/absent), microcalcification (present/absent), margin (well defined/poorly defined), shape (regular/irregular), and taller-than-wide shape (present/absent), and internal vascularity (present/absent). We defined microcalcification as calcifications <1.0 mm in diameter and multifocality as two or more PTCs during US examination.
Thyroidectomy plus neck dissection
The extent of thyroid surgery was performed based on the American Thyroid Association (ATA) management guidelines [5]. Once nodule malignancy was diagnosed form frozen section, central neck dissection was carefully conducted on the pre-laryngeal and pre-/para-tracheal lymph nodes.

Histopathologic analysis
Histopathologic results were interpreted by an experienced pathologist. With the utilization of frozen sections from the surgery, histopathological results were ultimately confirmed.

BRAF mutation analysis
According to previous researches, the capability to detect BRAFV600E mutation from US-guided FNAB cytologic specimens is not inferior to that in postoperative pathologic specimens [21, 22]. The polymerase chain reaction (PCR) conditions and primers for amplifying exon 15 in BRAF containing V600E mutation were established previously. Genomic DNA was extracted from cytologic specimens through the QIAamp DNA FFPE Tissue Kit (QIAGEN) following the manufacturer's instruction.

Statistical analysis
Statistical analysis was conducted using SPSS software (ver. 22.0; SPSS Inc., Chicago, IL, USA). Comparison of continuous and categorical variables were analyzed by Student's t-test and Pearson $X^2$ or Fisher's exact test, respectively. Independent predictors for cervical LNM were identified by multivariate logistic analysis. P value less than 0.05 was regarded to be significant.

Results
Participant demographics and US features
After the strict inclusion, 112 participants met the criteria and were included for further research. Of included participants, 35 (31.3%) were male and 77 (68.7%) were female. Among them, the mean age was 42.95 years old, and the range of age was from 21 to 66 years old. Briefly, 86 (76.8%) were less than 55 years, and 26 (23.2%) were 55 years and older. 65 participants (58.0%) had cervical CLNM, whereas 47 (42.0%) did not. No distant metastases were found in our research, predictive risk factors, including age patients younger than 55 years of age (OR = 3.457, $P = 0.006$), tumor size > 10 mm (OR = 8.138, $P = 0.003$) turned out to be risk predictors for cervical CLNM in participants with PTC (Fig. 2). Then, ROC curves were plotted, and the diagnostic value of the risk factors was discriminative with areas under the ROC curves of 0.612 (95% CI: 0.504–0.720), 0.664 (0.561–0.766), 0.626 (0.520–0.733), 0.606 (0.497–0.714) and 0.637 (0.533–0.742), respectively. Furthermore, their sensitivity and specificity were 86.2% and 36.2%, 64.6% and 68.1%, 78.5% and 46.8%, 89.2% and 31.9%, and 64.6% and 68.1%, respectively (Fig. 3a, Table 3). A multivariate logistic regression equation was established with these independent predictive factors: $P = 1/1 + \exp\left[-4.366 + 1.284 \times (\text{if nodule size} > 10 \text{ mm}) + 1.143 \times (\text{if microcalcification in nodule}) - 2.097 \times (\text{if concomitant Hashimoto's thyroiditis})ight]$. Suspicious US features with respect to solid component, marked hypo-/hypo-echogenicity, microcalcifications, irregular/lobulated margins, non-parallel orientation and taller than wide shape were presented in 105 (93.8%), 95 (84.8%), 76 (67.9%), 69 (61.6), 35 (31.3%) and 50 (44.6%) of PTC samples, respectively. Typically, BRAFV600E mutation was observed in 56 (50.0%) PTC patients. 22 (19.6%) participants were concomitant Hashimoto's thyroiditis, and 90 (80.4%) patients were without Hashimoto's thyroiditis.

Univariate analysis
As demonstrated in Table 1, participants less than 55 years of age have a higher frequency of cervical CLNM than those 55 years or older (86.2% vs 63.8%, $P = 0.006$). Among US characterizes of PTC, tumor diameter > 10 mm ($P = 0.001$) and microcalcification ($P = 0.007$) were remarkably correlated the presence of cervical CLNM. Other suspicious US characterizes, such as solid component, marked hypo-/hypo-echogenicity, irregular/lobulated margins, non-parallel orientation, and taller than wide shape were not related to cervical CLNM in PTC (all $P$ value > 0.05). In addition, concomitant Hashimoto's thyroiditis was more inclined to be non-cervical CLNM ($P = 0.008$). BRAFV600E mutation were more likely to present CLNM positive in PTC patients ($P = 0.007$).

Multivariate logistic analysis
Moreover, independent risk factors were determined after multivariate analysis (Table 2, Fig. 1). In our research, predictive risk factors, including age patients younger than 55 years of age (OR = 3.609, $P = 0.021$), tumor size >10 mm (OR = 3.457, $P = 0.011$), microcalcification (OR = 3.137, $P = 0.025$), non-concomitant Hashimoto's thyroiditis (OR = 8.138, $P = 0.001$), and BRAFV600E mutation (OR = 5.095, $P = 0.003$) turned out to be risk predictors for cervical CLMN in participants with PTC (Fig. 2). The receiver operating characteristic (ROC) curves were plotted, and the diagnostic value of the risk factors was discriminative with areas under the ROC curves of 0.612 (95% CI: 0.504–0.720), 0.664 (0.561–0.766), 0.626 (0.520–0.733), 0.606 (0.497–0.714) and 0.637 (0.533–0.742), respectively. Furthermore, their sensitivity and specificity were 86.2% and 36.2%, 64.6% and 68.1%, 78.5% and 46.8%, 89.2% and 31.9%, and 61.5% and 66.0%, respectively (Fig. 3a, Table 3). A multivariate logistic regression model was established with these independent predictive factors: $P = 1/1 + \exp\left[-4.366 + 1.284 \times (\text{if nodule size} > 10 \text{ mm}) + 1.143 \times (\text{if microcalcification in nodule}) - 2.097 \times (\text{if concomitant Hashimoto's thyroiditis})ight]$. Suspicious US features with respect to solid component, marked hypo-/hypo-echogenicity, microcalcifications, irregular/lobulated margins, non-parallel orientation and taller than wide shape were presented in 105 (93.8%), 95 (84.8%), 76 (67.9%), 69 (61.6), 35 (31.3%) and 50 (44.6%) of PTC samples, respectively. Typically, BRAFV600E mutation was observed in 56 (50.0%) PTC patients. 22 (19.6%) participants were concomitant Hashimoto's thyroiditis, and 90 (80.4%) patients were without Hashimoto's thyroiditis.
Table 1. Clinicopathologic and US features of cervical CLNM in PTC patients. N = number of papillary thyroid carcinoma; CLNM = central lymph node metastasis; PTC = papillary thyroid carcinoma.

| Characteristics                        | Total PTC with or without cervical LNM (N = 112) | P value |
|----------------------------------------|-------------------------------------------------|---------|
|                                        | Positive (N = 65)                            | Negative (N = 47) |       |
| Age                                    | 39.82 ± 10.29                                 | 47.28 ± 11.44    | P = 0.006 |
| < 55 years                             | 56 (86.2%)                                     | 30 (63.8%)       |       |
| ≥ 55 years                             | 9 (13.8%)                                      | 17 (36.2%)       |       |
| Gender                                 |                                                 |                   | P = 0.838 |
| Male                                   | 21 (32.3%)                                     | 14 (29.8%)       |       |
| Female                                 | 44 (67.7%)                                     | 33 (70.2%)       |       |
| Tumor size                             | 12 ± 4.6 mm                                    | 9.8 ± 4.6 mm     | P = 0.001 |
| > 10 mm                                | 42 (64.6%)                                     | 15 (31.9%)       |       |
| ≤ 10 mm                                | 23 (35.4%)                                     | 32 (68.1%)       |       |
| Multifocality                          |                                                 |                   | P = 0.832 |
| Multifocal                             | 18 (27.7%)                                     | 12 (25.5%)       |       |
| Unifocal                               | 47 (72.3%)                                     | 35 (74.5%)       |       |
| Location                               |                                                 |                   | P = 0.619 |
| Left                                   | 35 (53.8%)                                     | 21 (44.7%)       |       |
| Right                                  | 26 (40%)                                       | 23 (48.9%)       |       |
| Isthmus                                | 4 (6.2%)                                       | 3 (6.4%)         |       |
| Internal component                     |                                                 |                   | P = 1.000 |
| Solid                                  | 61 (93.8%)                                     | 44 (93.6%)       |       |
| Cystic                                 | 4 (6.2%)                                       | 3 (6.4%)         |       |
| Marked hypo-/hypo-echogenicity         |                                                 |                   | P = 1.000 |
| Present                                | 55 (84.6%)                                     | 40 (85.1%)       |       |
| Absent                                 | 10 (15.4%)                                     | 7 (14.9%)        |       |
| Microcalcification                      |                                                 |                   | P = 0.007 |
| Present                                | 51 (78.5%)                                     | 25 (53.2%)       |       |
| Absent                                 | 14 (21.5%)                                     | 22 (46.8%)       |       |
| Margin                                 |                                                 |                   | P = 0.555 |
| Irregular/lobulated                    | 42 (64.6%)                                     | 27 (57.4%)       |       |
| Regular                                | 23 (35.4%)                                     | 20 (42.6%)       |       |
| Orientation                            |                                                 |                   | P = 0.838 |
| Non-parallel                           | 21 (32.3%)                                     | 14 (29.8%)       |       |
| Parallel                               | 44 (67.7%)                                     | 33 (70.2%)       |       |
| Taller than wide                       |                                                 |                   | P = 0.705 |
| Present                                | 28 (43.1%)                                     | 22 (46.8%)       |       |
| Absent                                 | 37 (56.9%)                                     | 25 (53.2%)       |       |
| T stage                                |                                                 |                   | P = 0.180 |
| T1                                     | 29 (44.6%)                                     | 29 (61.7%)       |       |
| T2                                     | 35 (53.8%)                                     | 17 (36.2%)       |       |
| T3/T4                                  | 1 (1.5%)                                       | 1 (2.1%)         |       |
| Hashimoto's thyroiditis                |                                                 |                   | P = 0.008 |
| Concomitant                            | 7 (10.8%)                                      | 15 (31.9%)       |       |
| Non-concomitant                        | 58 (89.2%)                                     | 32 (68.1%)       |       |
| Internal vascularity                   |                                                 |                   | P = 0.846 |
| Present                                | 27 (41.5%)                                     | 18 (38.3%)       |       |
| Absent                                 | 38 (58.5%)                                     | 29 (61.7%)       |       |
| BRAF mutation                          |                                                 |                   | P = 0.007 |
| Positive                               | 40 (61.5%)                                     | 16 (34.0%)       |       |
| Negative                               | 25 (38.5%)                                     | 31 (66.0%)       |       |
Hashimoto's thyroiditis) + 1.628 × (if BRAFV600E mutation)] (Fig. 3b).

**Discussion**

PTC is recognized as one of the indolent diseases with a satisfactory prognosis, and the 5-year survival rate is nearly to 98% [23, 24]. Despite the death rate is negligible, the recurrent and metastatic PTC may happen in around 30% of PTC patients, which are largely associated with metastasis of cervical lymph nodes [25]. The routine neck dissection in the management for PTC remains a great deal of controversies. Not all cervical CLNM can be detected by US preoperatively, despite US technology is useful in identifying the stage of PTC [26].

US-guided FNAB technology is extensively performed to increase the diagnostic accuracy by cytologic or genomic examination [27]. Furthermore, the ability of BRAF detection in cytology is not inferior to that in pathologic specimens after surgery [28], which can provide us to pre-operatively analyze BARF status from FNAB cytologic specimens. BRAFV600E mutation is a somatic mutation that contributes to the transformation of valine to glutamate in the BRAF protein 600-bit codon, the abnormal cellular proliferation, and the malignant tumor formation [29]. Previous research have reported that BRAFV600E mutation is the critical gene of PTC, with about 73% mutation rate [30]. BRAFV600E mutation is associated with poor prognosis, cervical CLNM and recurrence of PTC [16, 31]. In our study, we detected BRAF status from FNAB tissues, and discovered BRAFV600E mutation was a predictive factor for CLNM.

Suspicious US features (size > 10 mm and microcalcification) and age < 55 years were risk predictors for cervical CLNM based on the multivariate logistic analysis. Hashimoto's thyroiditis was identified as a negatively predictive factor by multivariate logistic analysis. Tumor size is a critical factor estimated for the biological features of PTC, because tumor size can be readily obtained by preoperative US examination [32]. Malignant-looking PTC was more prevalence with extrathyroidal extension, cervical CLNM, and advanced stage than benign-looking PTC, especially when tumor diameter more than 10 mm.

### Table 2
Multivariate logistic regression analysis in predicting cervical CLNM in PTC patients. CLNM = central lymph node metastasis; PTC = papillary thyroid carcinoma

| PTC characteristics        | β Coefficient | Odds ratio | 95% Confidence Interval | P value |
|----------------------------|--------------|------------|-------------------------|---------|
| Age < 55 years             | 1.284        | 3.609      | 1.212–10.750            | 0.021   |
| Tumor size > 10 mm         | 1.241        | 3.457      | 1.328–9.002             | 0.011   |
| Microcalcification         | 1.143        | 3.137      | 1.155–8.521             | 0.025   |
| Non-Hashimoto’s thyroiditis| 2.097        | 8.138      | 2.326–28.468            | 0.001   |
| BRAF mutation              | 1.628        | 5.095      | 1.764–14.713            | 0.003   |

**Fig. 1** Forest plot of the risk factors of cervical CLNM in PTC patients
Other literatures have covered that tumor size was regarded as an independent predictors for nodal metastasis in PTC patients, which may be explained by the more extensive the PTC, the more proliferative and aggressive cancer cells spread to the lymph nodes. Microcalcification is the deposition of calcium salts resulted from vascular and fibrous hyperplasia, indicating the rapid growth of malignant cancer [37]. Thus, once microcalcification can be detected in PTC tissues, it is a strong indicator of the risk of nodal metastasis.
the lymph node in cervical scope must be evaluated more cautiously.

Age is a crucial variate in prognosis for patients bearing well-differentiated thyroid diseases. According to update-date AJCC guideline, 55 years of age was accustomed to being the cut-off value in staging [38]. Whether age is related to cervical CLNM in PTC patients, the present results are often inconsistent. For example, some reported that cervical CLNM was not related to age [39], while other findings argued that age less than 55 years of age was a predictor for cervical LNM [40, 41]. In this research, the younger age was largely related to a higher odds ratio of cervical CLNM and age younger than 55 years was a risk predictor for cervical CLNM, indicating cervical CLNM should be paid more attention in the younger PTC patients. Also, similar findings have been published by other authors [42, 43].

HT is the most common autoimmune thyroid disease, and the diagnosis of HT was based on the pathology of postoperative specimen in our research. Previous findings have implied a protective effect of HT in PTC patients, which is less associated with ETE, cervical CLNM, advanced stage and recurrence [44, 45]. A review summarized and updated the findings demonstrated that the benefit of HT in thyroid cancer patients depends on the phenotypes of infiltrative lymphocytes [46]. Infiltrative lymphocytes, including B cells, T cells, macrophages, NK cells and Th17 cell, were closely associated with a better outcome in PTC patients [47].

Limitations
There are still some limitations in our research. Firstly, our study was a retrospective study, and hence, selection bias was unavoidable. Secondly, the US detections were not prospectively standardized, i.e., ideally, every examination followed the same procedure. Thirdly, the disease-specific survival and recurrence of PTC were not analyzed attributed to short follow-up time. Therefore, the future multicenter and prospective research are urgently demanded to estimate the risk factors of nodal metastasis in PTC patients.

Conclusions
Our comprehensive analysis has determined age < 55 years old, size > 10 mm, microcalcification, non-concomitant Hashimoto's thyroiditis and BRAFV600E mutation are independent predictors for cervical CLNM in PTC patients. BRAFV600E mutation by pre-operative US-FNA technology synergized with clinicopathologic and US characteristics can guide the suitable therapeutic management of PTC. Overall, our research is expected to estimate PTC aggressiveness, thereby avoiding overtreatment and undertreatment, such as unnecessary prophylactic CLND, and providing emerging strategies for precise medicine for individual patients.

Acknowledgements
We are indebted to all the teams and patients who participated in this trial and made it possible.

Authors’ contributions
Zheng Zhang and Xin Zhang contributed equally to this work. Conceived and designed the experiments: Zheng Zhang and Baoding Chen. Performed the experiments: Shuangshuang Zhao and Yifei Yin. Contributed reagents/materials/analysis tools: Mengyuan Shang and Keke Wang. Wrote the paper: Zheng Zhang and Xincai Wu. All authors read and approved the final manuscript.

Funding
We greatly acknowledged the Medical Education Collaborative Innovation Fund of Jiangsu University (JDY2022002), the Fifth Phase "169 Project" Scientific Research Project of Zhenjiang City (YJLJ201931), and Social Development Program of Zhenjiang City (SH2019038; SH2021028).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations
Ethics approval and consent to participate
This study design followed the international regulations in accordance with The Declaration of Helsinki. Our research was approved by the Ethical Committee of the Affiliated Hospital of Jiangsu University (SYXLL20190225-2) and written informed consent was obtained from participants.

Table 3  ROC analysis of the independent factors and equation for predicting cervical CLNM in PTC patients. CI = confidence interval; CLNM = central lymph node metastasis; N = number of papillary thyroid carcinoma

|                     | Az   | 95% CI     | Cutoff value | Sensitivity | Specificity |
|---------------------|------|------------|--------------|-------------|-------------|
| Overall (N = 112)   |      |            |              |             |             |
| Age < 55y           | 0.612| 0.504–0.720| Age < 55y    | 0.862       | 0.362       |
| Tumor size > 10 mm  | 0.664| 0.561–0.766| Tumor size > 10 mm | 0.646 | 0.681       |
| Microcalcification   | 0.626| 0.520–0.733| Microcalcification | 0.785 | 0.468       |
| Non-Hashimoto's thyroiditis | 0.606 | 0.497–0.714 | Non-Hashimoto's thyroiditis | 0.892 | 0.319       |
| BRAF mutation       | 0.637| 0.533–0.742| BRAF mutation | 0.615       | 0.660       |
| Predictive equation | 0.845| 0.771–0.918| 0.593        | 0.738       | 0.851       |
References
1. Hauch A, Al-Qurayshi Z, Randolph G, Kandel E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol. 2014;21(12):3844–52. https://doi.org/10.1245/s10434-014-3846-8.
2. Han P, Kim H, Cho S, et al. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. Thyroid : official journal of the American Thyroid Association. 2016;26(4):532–42. https://doi.org/10.1089/thy.2015.0378.
3. Chen B, Zhang Z, Wang K, et al. A multivariable model of BRAF and ultrasonographic features for predicting the risk of central lymph node metastasis in cN0 papillary thyroid microcarcinoma. Cancer management and research. 2019;11:7211–7. https://doi.org/10.2147/cmar.s199921.
4. Colonna M, Uhry Z, Guizard A, et al. Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France. Cancer Epidemiol. 2015;39(4):511–8. https://doi.org/10.1016/j.canep.2015.04.013.
5. Cooper D, Doherty G, Haugen B, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid : official journal of the American Thyroid Association. 2009;19(11):1167–214. https://doi.org/10.1089/thy.2009.0110.
6. Zhan J, Zhang L, Yu Q, et al. Prediction of cervical lymph node metastasis with contrast-enhanced ultrasound and association between presence of BRAF and extrathyroidal extension in papillary thyroid carcinoma. Therapeutic advances in medical oncology. 2020;12:1758835920942367. https://doi.org/10.1177/1758835920942367.
7. Càlò P, Pisanò G, Meda F, et al. Total thyroidectomy without prophylactic central neck dissection in clinically node-negative papillary thyroid cancer: is it an adequate treatment? World journal of surgical oncology. 2014;12:152. https://doi.org/10.1186/1756-1872-12-152.
8. Mazzaferrri E, Doherty G, Steward D. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid : official journal of the American Thyroid Association. 2009;19(7):683–9. https://doi.org/10.1089/thy.2009.1578.
9. Viola D, Materazzi G, Valerio L, et al. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab. 2015;100(4):1316–24. https://doi.org/10.1210/jc.2014-2832.
10. Takashishi N, Chen H, Harris I, et al. Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. Cancer Cell. 2018;33(6):985-1003.e7. https://doi.org/10.1016/j.ccell.2018.05.005.
11. Gharib MH, Papini FE, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules: Executive Summary of Recommendations - Scien. Endocr Pract. 2010;16(3):468–75.
12. Kwak J, Han K, Yoon J, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology. 2011;260(3):892–9. https://doi.org/10.1148/radiol.11110206.
13. Zhang L, Yang J, Sun Q, et al. Risk factors for lymph node metastasis in papillary thyroid microcarcinoma: Older patients with fewer lymph node metastases. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2016;42(10):1478–82. https://doi.org/10.1016/j.ejso.2016.07.002.
14. Cho S, Lee T, Ku Y, Kim H, Lee G, Kim M. Central lymph node metastasis in papillary thyroid microcarcinoma can be stratified according to the number, the size of metastatic foci, and the presence of desmoplasia. Surgery. 2015;157(1):111–8. https://doi.org/10.1016/j.surg.2014.05.023.
15. Bhajee F, Nikolov Y. Molecular analysis of thyroid tumors. Endocr Pathol. 2011;22(3):126–33. https://doi.org/10.1002/ep.2017-9170-y.
16. O’Neill C, Bullock M, Chou A, et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surg. 2010;148(6):1139–45. https://doi.org/10.1016/j.surg.2010.09.005 discussion 1145–6.
17. Celik M, Bulbul B, Ayturk S, et al. The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer. Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina. 2020;17(1):30–4. https://doi.org/10.17392/1086-20.
18. Özçelik S, Bircan R, Sankaya Ş, et al. BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposure. Endokrynol Pol. 2019;70(5):401–8. https://doi.org/10.5603/EPa.2019.0025.
19. Virk RK, Dyke A, Finkelstein A, et al. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Modern Pathol Official United States of Canada Acad Path Inc. 2013;26(1):162–70.
20. Li M, Zhu XY, Lv J, Lu K, Wu ZS. Risk factors for predicting central lymph node metastasis in papillary thyroid microcarcinoma (CN0): a study of 273 resections. Eur Rev Med Pharmacol Sci. 2017;21(17):3801–7.
21. Jin YK, Kim EK, Moon HJ, Min JK. Association of BRAFV600E Mutation with Poor Clinical Prognostic Factors and Sonographic Features in Korean Patients with Papillary Thyroid Microcarcinoma. Radiology. 2009;253:854.
22. Chen B, Zhang Z, Wang K, Shang M, Xu X. A multivariable model of BRAFV600E and ultrasonographic features for predicting the risk of central lymph node metastasis in cN0 papillary thyroid microcarcinoma. Cancer Management and Research. 2019;11:2711–7.
23. Chen B, Xu H, Zhang Y, et al. The diagnostic performances of conventional strain elastography (SE), acoustic radiation force impulse (ARFI) imaging and point shear-wave speed (pSWS) measurement for non-calcified thyroid nodules. Clin Hemorheol Micropor. 2017;65(3):259–73. https://doi.org/10.3233/ch-16178.
24. Chen B, Zhang Z, Wang K, et al. Association of BRAFV600E mutation with ultrasonographic features and clinicopathologic characteristics of papillary thyroid microcarcinoma: A retrospective study of 116 cases. Clin Hemorheol Micropor. 2019;73(4):454–52. https://doi.org/10.3233/ch-190568.
25. Brown R, de Souza J, Cohen E. Thyroid cancer: burden of illness and management of disease. J Cancer. 2011;2:193–9. https://doi.org/10.7150/jca.2.193.
26. Gharib H, Papini E, Garber J, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ASSOCIAZIONE MEDICI ENDOCRINOLOGI MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND MANAGEMENT OF THYROID NODULES–2016 UPDATE. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2016;22(5):622–39. https://doi.org/10.4158/EP.2016.05.1.
27. Izquierdo R, Shankar R, Kort K, Khurana K. Ultrasound-guided fine-needle aspiration in the management of thyroid nodules in children and adolescents. Thyroid : official journal of the American Thyroid Association. 2009;19(7):703–5. https://doi.org/10.1089/thy.2009.0058.
28. Kwak J, Kim E, Chung W, Moon H, Kim M, Choi J. Association of BRAF(V600E) mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiol. 2009;253(3):854–60. https://doi.org/10.1148/radiol.253309047.
29. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(3):742–62. https://doi.org/10.1210/er.2007-0007.
31. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol. 2010;321(1):86–93. https://doi.org/10.1016/j.mce.2009.10.012.

32. Chen Y, Sadow P, Suh H, et al. BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis. Thyroid: official journal of the American Thyroid Association. 2016;26(2):248–55. https://doi.org/10.1089/thy.2015.0391.

33. Zhang F, Zheng B, Yu X, Wang X, Wang S, Teng W. Risk Factors for Contralateral Occult Carcinoma in Patients With Unilateral Papillary Thyroid Carcinoma: A Retrospective Study and Meta-Analysis. Front Endocrinol. 2021;12. 675643. https://doi.org/10.3389/fendo.2021.675643.

34. Nam S, Shin J, Han B, et al. Preoperative ultrasonographic features of papillary thyroid carcinoma predict biological behavior. J Clin Endocrinol Metab. 2013;98(4):1476–82. https://doi.org/10.1210/jc.2012-4072.

35. Xu S, Yao J, Zhou W, Chen L, Zhan W. Clinical characteristics and ultrasonographic features for predicting central lymph node metastasis in clinically node-negative papillary thyroid carcinoma without capsule invasion. Head Neck. 2019;41(11):3984–91. https://doi.org/10.1002/hed.25941.

36. Jianming L, Jibin L, Linxue Q. Suspicious ultrasound characteristics correlate with multiple factors that predict central lymph node metastasis of papillary thyroid carcinoma. Significant role of HBME-1. Eur J Radiol. 2020;123: 108801. https://doi.org/10.1016/j.ejrad.2019.108801.

37. Wei X, Wang M, Wang X, et al. Prediction of cervical lymph node metastases in papillary thyroid microcarcinoma by sonographic features of the primary site. Cancer Biol Med. 2019;16(3):587–94. https://doi.org/10.20892/jissn.2095-3941.2018.0310.

38. Iannuccilli J, Cronan J, Monchik J. Risk for malignancy of thyroid nodules as assessed by sonographic criteria: the need for biopsy. Journal of ultrasound in medicine: official journal of the American Institute of Ultrasound in Medicine. 2004;23(11):1455–64. https://doi.org/10.7863/jum.2004.23.11.1455.

39. Lamartina L, Grani G, Arvat E, et al. 8th edition of AJCC/TNM staging system of thyroid cancer: what to expect. Endocr Rel Cancer. 2017;25:ERC-17-0453.

40. Liu Z, Wang L, Yi P, Wang C, Huang T. Risk factors for central lymph node metastasis of patients with papillary thyroid microcarcinoma: a meta-analysis. Int J Clin Exp Pathol. 2014;7(3):932–7.

41. Lin D, Qu N, Shi R, Lu Z, Ji Q, Wu W. Risk prediction and clinical model building for lymph node metastasis in papillary thyroid microcarcinoma. Onco Targets Ther. 2016;9:5307–16. https://doi.org/10.2147/ott.s10913.

42. Ahn B, Kim J, Jeong H, Lee J, Chang E, Kim Y. Predictive factors of central lymph node metastasis in papillary thyroid carcinoma: Annals of surgical treatment and research. 2015;88(2):63–8. https://doi.org/10.4174/asr.2015.88.2.63.

43. Zhao Q, Ming J, Liu C, et al. Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. Ann Surg Oncol. 2013;20(3):746–52. https://doi.org/10.1245/sjo.10434.012.26524.2

44. Hong Y, Yan C, Mo G, et al. Conventional US, elastography, and contrast enhanced US features of papillary thyroid microcarcinoma predict central compartment lymph node metastases. Sci Rep. 2015;5:7748. https://doi.org/10.1038/srep07748.

45. Lang B, Chai Y, Cowling B, Min H, Lee K, Youn Y. Is BRAF(V600E) mutation a marker for central nodal metastasis in small papillary thyroid carcinoma? Endocr Relat Cancer. 2014;21(2):285–95. https://doi.org/10.1530/erc-13-0291.

46. Kim S, Woo J, Lee J, et al. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma. Endocr Relat Cancer. 2016;23(1):27–34. https://doi.org/10.1530/erc-15-0408.

47. Nagayama Y. Thyroid Autoimmunity and Thyroid Cancer - The Pathogenic Connection: A 2018 Update. Hormone metabol res = Hormones et metabolisme. 2018;50(12):922–31. https://doi.org/10.1055/a-0645-4593.

48. Ding J, Wu W, Fang J, Zhao J, Jiang L. Male sex is associated with aggressive behaviour and poor prognosis in Chinese papillary thyroid carcinoma. Sci Rep. 2020;10(1):4141. https://doi.org/10.1038/s41598-020-60199-9.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.